checkAd

     173  0 Kommentare OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

    OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

    NANTES, France, June 24, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center.

    This exclusive and worldwide agreement with Memorial Sloan Kettering Cancer Center (MSK) covers OSE Immunotherapeutics’ patent rights and jointly owned OSE/MSK patent rights in the field of Chimeric Antigen Receptor (CAR) cell therapy for the treatment of Interleukin-7 Receptor (IL-7R) expressing cancers, in particular hematological tumors such as Acute Lymphoblastic Leukemia. As part of this agreement, MSK will lead the research, development, and commercialization efforts, and subsequently share potential future revenues with OSE Immunotherapeutics.

    Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, said: “We are very pleased to reinforce our collaboration with one of the world’s most renowned US cancer hospitals in oncology and in particular in the field of CAR-T cell therapies. Based on their pioneering expertise in this area, we look forward to the clinical exploration of a potential breakthrough therapy option for IL-7R expressing cancer patients”.

    “I am excited for the next steps in translation of IL-7R targeted CARs to clinical trials treating IL-7R expressing tumor bearing patients at MSK," said Prasad S. Adusumilli, MD, FACS, Deputy Chief and Attending, Thoracic Service, and Vice Chair for Translational Research, Department of Surgery, at MSK. Dr. Adusumilli holds the Min H. & Yu-Fan C. Kao Chair in Thoracic Cancer at MSK. His laboratory team investigated and developed therapeutic strategies using IL-7R CAR T cells.

    This new agreement is based on the initial multi-year research collaboration between MSK and OSE Immunotherapeutics to explore the preclinical potential of a non-antagonist IL-7R monoclonal antibody directed against the alpha chain of IL-7R used either as a therapeutic antibody or for the design of innovative CAR-T cells for cancer indications expressing high level of IL-7R.

    About OSE Immunotherapeutics

    OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I).
    The Company’s current well-balanced first-in-class clinical pipeline includes:

    • Tedopi (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company’s most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi in combination are ongoing in solid tumors.
    • OSE-279 (anti-PD1): first positive results in the ongoing Phase 1/2 in solid tumors.
    • OSE-127 - lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia (OSE Immunotherapeutics).
    • FR-104/VEL-101 (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); successful Phase 1 in the US (sponsor Veloxis Pharmaceuticals, Inc.).
    • Anti-SIRPα monoclonal antibody developed in partnership with Boehringer Ingelheim in advanced solid tumors and cardiovascular-renal-metabolic diseases (CRM); positive Phase 1 dose escalation results in monotherapy and in combination; Phase 2 in CRM diseases planned to be initiated end of 2024.
    • ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation.

    OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies:

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies NANTES, France, June 24, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the …

    Schreibe Deinen Kommentar

    Disclaimer